1,149 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Resurgent Financial Advisors LLC

Resurgent Financial Advisors LLC bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,149 shares of the pharmaceutical company’s stock, valued at approximately $521,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Colonial Trust Co SC increased its holdings in Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 38 shares during the period. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $29,000. IMG Wealth Management Inc. increased its holdings in Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 50 shares during the period. Ares Financial Consulting LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $33,000. Finally, Archer Investment Corp increased its holdings in Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock worth $34,000 after acquiring an additional 35 shares during the period. Institutional investors own 90.96% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex announced new data on CASGEVY showing clinical benefits in patients ages 5 and older with severe sickle cell disease or transfusion-dependent beta thalassemia, including pediatric data consistent with the therapy’s profile in older patients. The company also said it is making additional global regulatory submissions, which could expand the drug’s commercial opportunity. Article Title
• Positive Sentiment: Several recent items point to supportive Wall Street views, including a “Moderate Buy” consensus and multiple higher price targets, suggesting analysts still see upside despite the stock’s recent strength.
• Neutral Sentiment: Vertex presented at the Goldman Sachs Global Healthcare Conference, but no major new financial guidance or pipeline surprise was highlighted in the available summary. Article Title
• Neutral Sentiment: A senior executive sold shares under a pre-arranged 10b5-1 plan. While this can draw attention, the sale appears routine rather than a sign of negative business developments. Article Title
• Negative Sentiment: Erste Group trimmed its FY2027 EPS estimate for Vertex slightly, which may have limited enthusiasm a bit, though the change was modest and the outlook remains above current-year consensus. Article Title

Insider Activity

In other news, EVP Joy Liu sold 1,104 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the sale, the executive vice president owned 20,729 shares of the company’s stock, valued at approximately $8,810,239.58. This represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 1,745 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $450.00, for a total transaction of $785,250.00. Following the completion of the sale, the chief marketing officer directly owned 21,015 shares of the company’s stock, valued at $9,456,750. This trade represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 11,133 shares of company stock valued at $4,973,106. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $445.04 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $507.92. The stock has a market capitalization of $112.95 billion, a price-to-earnings ratio of 26.40, a price-to-earnings-growth ratio of 1.86 and a beta of 0.30. The company has a fifty day moving average of $437.19 and a 200-day moving average of $452.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the prior year, the company earned $4.06 EPS. The firm’s revenue was up 8.3% on a year-over-year basis. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Canaccord Genuity Group cut their price target on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. HC Wainwright boosted their price target on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Sanford C. Bernstein cut their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Finally, Truist Financial assumed coverage on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 27th. They issued a “buy” rating and a $542.00 price target for the company. Twenty-two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $555.91.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.